Neuroprotection of medical IOP-lowering therapy.

Neuroprotection of medical IOP-lowering therapy.

Item
http://www.wikidata.org/entity/Q38120187
Development of a Δ9-Tetrahydrocannabinol Amino Acid-Dicarboxylate Prodrug With Improved Ocular Bioavailability.Pharmacotherapy of glaucoma.Suppression of TGF-β pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitroGlaucoma -state of the art and perspectives on treatment.Decelerated neurodegeneration after intravitreal injection of α-synuclein antibodies in a glaucoma animal model.Neuroprotection by (endo)cannabinoids in glaucoma and retinal neurodegenerative diseases.Effects of 0.2% brimonidine and 0.2% brimonidine-0.5% timolol on intraocular pressure and pupil size in normal equine eyes.Candidate proteins from predegenerated nerve exert time-specific protection of retinal ganglion cells in glaucoma.Novel therapeutics in glaucoma management.A thermally triggered in situ hydrogel from poly(acrylic acid-co-N-isopropylacrylamide) for controlled release of anti-glaucoma drugs
P2860

Neuroprotection of medical IOP-lowering therapy.

Item
http://www.wikidata.org/entity/Q38120187
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Neuroprotection of medical IOP-lowering therapy.
@en
type
label
Neuroprotection of medical IOP-lowering therapy.
@en
prefLabel
Neuroprotection of medical IOP-lowering therapy.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P6179
P698
P356
P1433
P1476
Neuroprotection of medical IOP-lowering therapy.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P6179
P698